The study, led by the University of Edinburgh, could contribute to the development of new drugs that stop cancerous cells multiplying and so prevent the spread of the disease.
Such treatments - known as anti-mitotic drugs - would have the potential to limit the side-effects associated with some chemotherapy drugs, such as damage to healthy nerve cells. The development could also help optimise personalised chemotherapy treatments for individual cancer patients.
Scientists carried out a series of experiments to study how various proteins involved in the control of cell division interact with each other in cells. They used high-resolution microscopy to view the cells in 3D and determine the position of each of the proteins. Crucially, they were able to pinpoint how one key protein binds and triggers the activation of a further two key enzymes, each of which is involved with ensuring that cell division takes place correctly.
Both enzymes studied had previously been identified as targets for development of anti-cancer drugs. The latest discovery adds to scientists' understanding of how better drugs might be designed that stop the activity of both enzymes. The study, published in the Public Library of Science Biology, was supported by the Wellcome Trust.
Dr Mar Carmena of the University of Edinburgh's School of Biological Sciences, who took part in the study, said: "Cell division is a complex and tightly regulated process, and when it goes out of control this can lead to cancer. The greater our understanding of the proteins that control cell division, the better equipped scientists will be to design more effective treatments against cancer."
Advertise with us - Download World Pharma News' Media Pack Read more
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more